20 Jul S. Biomedics
Saeil Kang, CEO
Oct. | 2:15pm | FLW Ballroom G
Seoul, Korea
(KOSDAQ: 304360)
S.Biomedics focuses on developing disease-specific cell therapies utilizing two proprietary, high-efficiency platforms. One of our core platforms, TED, enables robust and consistent differentiation of pluripotent stem cells into lineage-specific neural precursor cells. Using TED, we developed TED-A9, a cell therapy candidate for Parkinson’s disease comprising ventral midbrain dopaminergic precursors derived from human embryonic stem cells. A Phase 1/2a clinical trial (NCT05887466) was conducted in patients with moderate-to-severe Parkinson’s disease to assess safety and exploratory potential clinical outcomes. Twelve patients received bilateral putamen transplantation of a low (3.15 million cells) or high (6.30 million cells) dose of A9-DPC. No dose-limiting toxicities or graft-related adverse events were reported. At 12 months, improvements in motor function (off-medication MDS-UPDRS Part III and Hoehn & Yahr) were observed, especially in the high-dose group. These findings support the safety and therapeutic potential of TED-A9 in Parkinson’s disease.
